Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma study: TORL-5-700 vs TORL-5-700 at MTD/RP2D
Official title A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
ClinicalTrials.gov ID: NCT07439653
What this study is testing
What is TORL-5-700?
TORL-5-700 is an investigational medicine, being studied as a potential treatment for histologically confirmed relapsed or refractory b-cell non-hodgkin lymphoma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out how safe TORL-5-700 is, how well people tolerate it, and whether it shows any anti‑cancer activity.
- Who it's for
- Adults with confirmed relapsed or refractory B‑cell non‑Hodgkin lymphoma.
- What's involved
- Participants will receive TORL-5-700 by itself or together with other treatments, and will have regular clinic visits for dosing, safety checks, and lab tests.
- Time commitment
- The trial runs for several months with multiple visits to the clinic for treatment and monitoring.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- At least 1 measurable lesion per Lugano criteria.
- Tumor tissue is available.
- Adequate organ function
You likely can't join if
- T-cell lymphoma
- CLL or SL
- Burkitt lymphoma and high-grade B-cell lymphoma
- CNS involvement
- Peripheral neuropathy \> Grade 2
- Uncontrolled medical conditions
See the full eligibility criteria
- Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- At least 1 measurable lesion per Lugano criteria.
- Tumor tissue is available.
- Adequate organ function
- T-cell lymphoma
- CLL or SL
- Burkitt lymphoma and high-grade B-cell lymphoma
- CNS involvement
- Peripheral neuropathy \> Grade 2
- Uncontrolled medical conditions
- Viral infections
The study team makes the final eligibility decision.
Where it is enrolling
- Fullerton, California, United States
- Los Alamitos, California, United States
- Santa Monica, California, United States
- Stanford, California, United States
- Miami, Florida, United States
- Iowa City, Iowa, United States
- Wichita, Kansas, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Fullerton, California, United States; Los Alamitos, California, United States; Santa Monica, California, United States; Stanford, California, United States; Miami, Florida, United States; Iowa City, Iowa, United States and 3 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.